Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development	$ 16,965	$ 10,707	$ 46,228	$ 30,176
General and administrative	7,168	7,119	24,861	15,068
Total operating expenses	24,133	17,826	71,089	45,244
Loss from operations	(24,133)	(17,826)	(71,089)	(45,244)
Grant income	2,959	2,079	3,934	6,499
Other income, net	985	73	1,651	231
Net loss	(20,189)	(15,674)	(65,504)	(38,514)
Unrealized loss on available-for-sale securities	(547)	(33)	(2,084)	(29)
Comprehensive loss attributable to common stockholders	$ (20,736)	$ (15,707)	$ (67,588)	$ (38,543)
Net loss per share attributable to common stockholders, basic	$ (0.53)	$ (0.42)	$ (1.74)	$ (1.05)
Net loss per share attributable to common stockholders, diluted	$ (0.53)	$ (0.42)	$ (1.74)	$ (1.05)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	37,817,724	37,312,356	37,693,830	36,773,100
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	37,817,724	37,312,356	37,693,830	36,773,100